Contact this trialFirst, we need to learn more about you.
Monoclonal Antibodies
Canakinumab for Duchenne Muscular Dystrophy
Recruiting1 awardPhase 1 & 2
Washington, District of Columbia
This trial is investigating the effects of canakinumab, an anti-interleukin 1 beta (IL1β) antibody, on clinical safety and potential clinical efficacy in young boys with Duchenne Muscular Dystrophy (DMD) who are most likely to have high levels of muscle inflammation.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.